Leap Therapeutics Closes $58.9M PIPE, Advances Digital Asset Strategy and Sirexatamab Trials

Leap Therapeutics Inc: Company Overview

Leap Therapeutics Inc (Nasdaq: LPTX) is a Cambridge, Massachusetts-based clinical-stage biopharmaceutical company focused on targeted and immuno-oncology therapeutics. As of November 12, 2025, its stock closed at $0.5655, reflecting a 29.26% increase with a trading volume of 5,550,914 shares on the Nasdaq exchange. Leap’s lead clinical asset, sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, with indications in esophagogastric, gynecologic, and colorectal cancers.

Corporate Structure and Expertise

Leap Therapeutics operates with a team of 11–50 employees headquartered in Cambridge, MA. The board of directors includes experienced professionals such as Christopher Mirabelli, PhD (HealthCare Ventures), Thomas Dietz, PhD (Waypoint Holdings), and Douglas Onsi (Cypherpunk Technologies). The company’s scientific advisory board consists of notable academic and clinical researchers such as David Tuveson, MD, PhD (Cold Spring Harbor Laboratory) and Eileen O’Reilly, MD (Memorial Sloan Kettering).

Immuno-oncology by National Cancer Institute

Recent Developments and News

• October 6, 2025: Leap Therapeutics announced a $58.88 million private investment in public equity (PIPE) led by Winklevoss Capital, intended to establish a digital asset treasury strategy. The transaction involves 95,849,353 common shares or pre-funded warrants and additional warrants for 71,887,008 shares at an exercise price of $0.5335 per share, with an aggregate exercise price of $0.61439 per unit.
• October 19, 2025: The company presented randomized Phase 2 data for sirexatamab in second-line colorectal cancer at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, indicating improved progression-free survival and overall survival in patients with high DKK1 expression.
• April 23, 2025: Leap hosted a virtual event featuring Zev A. Wainberg, MD (UCLA), discussing the potential of sirexatamab in the treatment of microsatellite stable colorectal cancer.

Financial and Strategic Analysis

The $58.88 million PIPE financing is intended to enhance Leap’s financial position and support two strategic areas: the continued development of its oncology pipeline and the implementation of a digital asset treasury strategy. Through the partnership with Winklevoss Capital, the company aims to utilize expertise in blockchain to explore digital asset opportunities while retaining essential funds for clinical programs. As a part of this financing, Leap will expand its board to 12 members, allowing Winklevoss Capital to nominate two directors, including the board chair.

Market Position and Industry Context

Leap Therapeutics operates within the competitive immuno-oncology sector, where humanized monoclonal antibodies and combination therapies are significant areas of development. Its pipeline includes:

• Sirexatamab (DKN-01): in Phase 2/3 trials for gastric, colorectal, and endometrial cancers in combination with chemotherapy or anti-PD-1 agents.
• FL-301: a Claudin18.2-targeting antibody in clinical development for gastric and pancreatic cancer.
• FL-501: a growth and differentiation factor 15 (GDF-15) antibody in preclinical development.

The company’s focus on DKK1 and Claudin18.2 positions it within the broader landscape of immuno-oncology, while its digital asset treasury strategy reflects a trend of biotech firms considering varied financial strategies.

tl;dr

As of November 12, 2025, Leap’s shares trade at $0.5655, with a 29.26% increase on heavy volume. On October 6, 2025, the company closed a $58.88 million PIPE led by Winklevoss Capital to begin a digital asset treasury strategy. On October 19, 2025, Leap presented data from Phase 2 trials for sirexatamab at ESMO, indicating survival benefits in patients with high DKK1 expression in colorectal cancer. Proceeds from the PIPE are designated for clinical trials across its pipeline—DKN-01, FL-301, and FL-501—and support an expansion of its board to 12, with two seats allocated for Winklevoss Capital. Upcoming milestones include additional trial readouts and updates on digital asset initiatives.